undamentalytics Newsletter

Ispecimen Inc. cash flow statement

In fiscal 2025, Ispecimen Inc.'s operations generated −$4.2m of cash; it spent $454 on capital projects, leaving free cash flow of −$4.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ispecimen Inc.: cash flow statement, annual
Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−0−11−6−6−8−4−7
Depreciation and amortisation0002221
Stock-based pay0110000
Capital spending0000000
Free cash flow−0−11−6−6−8−4−7
Free cash flow after stock pay−0−11−7−6−9−4−7
Shares issued—2——04—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ISPC vs YDESISPC vs QSIACON vs ISPC

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Ispecimen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ispecimen Inc.